KFU. Card publication. EXACERBATION OF CHRONIC SPONTANEOUS URTICARIA SYMPTOMS IN COVID-19 PATIENTS, CASE REPORT

KAZAN
FEDERAL UNIVERSITY

- RUS
- 中文
- ES

EXACERBATION OF CHRONIC SPONTANEOUS URTICARIA SYMPTOMS IN COVID-19 PATIENTS, CASE REPORT

Form of presentation

Articles in international journals and collections

Year of publication

2022

��

��

Authors, employees of KFU

Klyucharova Aliya Rafailovna, author

Martynova Ekaterina Vladimirovna, author

Rizvanov Albert Anatolevich, author

Khaybullina Svetlana Francevna, author

Bibliographic description in the original language

EXACERBATION OF CHRONIC SPONTANEOUS URTICARIA SYMPTOMS IN COVID-19 PATIENTS, CASE REPORT Klyucharova A., Martynova E., Rizvanov A., Khaiboullina S. BioNanoScience. 2022. T. 12. � 4. S. 1482-1488

Annotation

BioNanoScience

Keywords

URTICARIA ? COVID-19 ? Chronic spontaneous urticaria

The name of the journal

BioNanoScience

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=283447&p_lang=2

Resource files

File name	Size (MB)	Format
F_s12668_022_01007_8.pdf	0,79	pdf	show / download

Full metadata record

Field DC	Value	Language
dc.contributor.author	Klyucharova Aliya Rafailovna	ru_RU
dc.contributor.author	Martynova Ekaterina Vladimirovna	ru_RU
dc.contributor.author	Rizvanov Albert Anatolevich	ru_RU
dc.contributor.author	Khaybullina Svetlana Francevna	ru_RU
dc.date.accessioned	2022-01-01T00:00:00Z	ru_RU
dc.date.available	2022-01-01T00:00:00Z	ru_RU
dc.date.issued	2022	ru_RU
dc.identifier.citation	EXACERBATION OF CHRONIC SPONTANEOUS URTICARIA SYMPTOMS IN COVID-19 PATIENTS, CASE REPORT Klyucharova A., Martynova E., Rizvanov A., Khaiboullina S. BioNanoScience. 2022. �. 12. � 4. �. 1482-1488	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=283447&p_lang=2	ru_RU
dc.description.abstract	BioNanoScience	ru_RU
dc.description.abstract	Chronic spontaneous urticaria (CSU) is characterized by wheals lasting more than 6 weeks and can be accompanied by angioedema. Treatment of the disease varies depending on the severity and includes frst-line therapeutics such as nonsedative antihistamines. Second- and third-line treatments are used in severe and uncontrolled form of CSU. Environmental exposure and infections could trigger worsening symptoms. The goal of this study is to assess the efect of SARS-CoV-2 infection on CSU symptoms and the efcacy of the second- and third-line therapeutics for CSU management in COVID-19 patients. Our fndings show that SARS-CoV-2 infection exacerbates CSU symptoms. Worsening of disease was indicated by decreased Urticaria Control Test (UCT) and increased Urticaria Activity Score (UAS). Treatment management was modifed by switching to second- and third-line therapeutics; however, therapeutic control was achieved only in one patient. Our data demonstrates that SARS-CoV-2 infection contributes to the severity of CSU. Symptoms of CSU are more challenging to manage and require changes in treatment protocol, including second- and third-line therapeutics. We believe that severe infammation triggered by SARS-CoV-2 infection contributes to the worsening of CSU symptoms.	ru_RU
dc.language.iso	ru	ru_RU
dc.subject		ru_RU
dc.title	EXACERBATION OF CHRONIC SPONTANEOUS URTICARIA SYMPTOMS IN COVID-19 PATIENTS, CASE REPORT	ru_RU
dc.type	Articles in international journals and collections	ru_RU